SCHEMBL3428539

SCHEMBL3428539

CC(N)(C#N)COc1ccc(C(N)=O)cc1C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
S1PR1 P21453 1/20 0.41
SSTR4 P31391 1/20 0.40
AAK1 Q2M2I8 7/20 0.40
CYP3A4 P08684 3/20 0.40
THRA P10827 1/20 0.39
THRB P10828 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
MAPK1 P28482 1/20 0.39
MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3176541 0.83 S1PR1 (0.48) KMT2AKDM4EMEN1CYP2D6MAPT
SCHEMBL13525291 0.77 KMT2A (0.38) KMT2AKDM4EMEN1CYP2D6MAPT
SCHEMBL3425494 0.77 SLC6A2 (0.45) KMT2AKDM4EMEN1CYP2D6MAPT
SCHEMBL3427596 0.77 S1PR1 (0.46) KMT2AKDM4EMEN1CYP2D6MAPT
SCHEMBL13536362 0.77 EPHX2 (0.38) KMT2AKDM4EMEN1CYP2D6MAPT
SCHEMBL3597416 0.76 AR (0.43) SSTR4AAK1CYP3A4MRGPRX4RXRA
SCHEMBL628125 0.74 MAPK1 (0.54) KMT2AKDM4EMEN1CYP2D6MAPT
Hydrochloric Acid SCHEMBL7840484 0.73 MAPK1 (0.53) KMT2AKDM4EMEN1CYP2D6MAPT
SCHEMBL3168510 0.72 AAK1 (0.42) SSTR4AAK1CYP3A4MRGPRX4
SCHEMBL31413934 0.72 AAK1 (0.42) SSTR4AAK1CYP3A4MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642379-B2 Aminoacetonitrile derivatives and their use for controlling parasites on warm-blooded animals NOVARTIS AG (CH) 2010-01-05 US disclosed
US-20080194693-A1 Aminoacetonitrile Derivatives and Their Use for Controlling Parasites on Warm-Blooded Animals NOVARTIS AG (CH) 2008-08-14 US disclosed
EP-1758849-A1 AMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES ON WARM-BLOODED ANIMALS Novartis AG (CH) 2007-03-07 EP disclosed
WO-2005121075-A1 AMINOACETONITRILE DERIVATIVES AND THEIR USE FOR CONTROLLING PARASITES ON WARM-BLOODED ANIMALS NOVARTIS AG (CH) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194693-A1 Aminoacetonitrile Derivatives and Their Use for Controlling Parasites on Warm-Blooded Animals MB, ACHE, ADORA2B KMT2A 1345/4885KDM4E 2224/4885MEN1 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.